pyridostigmine bromide has been researched along with Morbid Obesity in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schumann, R; Siddiqui, ZI; Tarnoff, M | 1 |
| Cappa, M; Ghigo, E; Locatelli, V; Loche, S; Müller, EE; Pintor, C; Puggioni, R | 1 |
2 other study(ies) available for pyridostigmine bromide and Morbid Obesity
| Article | Year |
|---|---|
Minimally invasive gastric bypass in a morbidly obese patient with myasthenia gravis.
Topics: Anesthesia, Inhalation; Anesthetics, Local; Cholinesterase Inhibitors; Comorbidity; Female; Gastric Bypass; Humans; Laparoscopy; Middle Aged; Myasthenia Gravis; Neostigmine; Obesity, Morbid; Pyridostigmine Bromide | 2004 |
Pyridostigmine counteracts the blunted growth hormone response to growth hormone-releasing hormone of obese children.
Topics: Adolescent; Child; Child, Preschool; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Insulin-Like Growth Factor I; Obesity; Obesity, Morbid; Pyridostigmine Bromide; Receptors, Cholinergic | 1989 |